Home›Companies›Saccade
Saccade

World's Earliest Test for Alzheimer's Biomarkers

Alzheimer's testing today is bottlenecked around the onset of symptoms, when the damage is already done. Current treatments, including the FDA-approved drugs released in 2024, don't reverse the disease; they only slow it down. Earlier detection means earlier intervention. Eye movement changes linked to Alzheimer's surface sooner than any other biomarker, up to 15 years before symptoms appear. We deliver a 15-minute VR assessment delivered to patients in longevity clinics: • Tasks: patients perform visual tasks designed by neurologists to trigger a distinct oculomotor response in people with Alzheimer's or on its path • Hardware: our patent-pending attachment connects to any VR headset on the market and captures these eye movement patterns. • Analysis: the patterns are compared against our ML model to produce a risk analysis. Once classified, patients can access new interventions, such as the FDA-approved drugs. They're also referred to longevity practices, neurology practices or both, depending on their stage of decline. Testing for the earliest biomarkers allows the earliest possible intervention. In some cases, that slows the disease enough that patients outlive the onset of symptoms and never face memory loss in their lifetime.
Active Founders
Shreyas Bhardwaj
Shreyas Bhardwaj
Founder/CEO
Founder at Saccade. Prev built medical devices for hospitals; soft robotics researcher
Company Launches
Saccade: World's Earliest Test for Alzheimer's Biomarkers
See original launch post

TL;DR: Saccade is a 15-minute VR test that catches Alzheimer’s biomarkers earlier than ever before. That lets people start lifestyle changes and new FDA-approved drugs years sooner, when they work best. Sometimes that pushes symptoms past life expectancy, so they never show up.
We’re live in San Francisco clinics, testing people in their 30s and older for early risk indicators.
You can book a test at saccade.health today.

https://youtu.be/2H0dh5Hnd_Q

Problem
Current Alzheimer's testing only screens patients after clear symptoms appear, at which point an individual has already suffered significant cognitive decline. New FDA-approved drugs have been proven to slow this decline, but not reverse it. By the time most people get their diagnosis, they've missed their best window to act.

Insight
Eye movement changes linked to Alzheimer's can be detected up to 15 years before symptoms appear - earlier than any other markers we can screen for. Our product is designed to service those exact changes, giving patients the insight they need to act now.

uploaded image

Product

  • Tasks: users complete visual tasks designed by neurologists that trigger distinct oculomotor responses in people with early-stage, pre-symptomatic Alzheimer's
  • Hardware: our patent-pending attachment connects to any VR headset on the market and captures high-precision recordings of eye movement patterns.
  • Analysis: the patterns are analyzed by our proprietary ML model to produce a risk score.

Next Steps for Patients
Once classified into one of three risk categories, patients can start interventions ranging from preventative longevity practices, further neurological evaluations, and new FDA-approved drugs. Starting treatment early can significantly slow the progression of the disease, allowing some patients to outlive the onset of symptoms and never suffer from memory loss in their lifetime.

Get tested today: Sign up at saccade.health and schedule a screening today.

Asks
Intros to US longevity practices and clinics that want to offer early Alzheimer’s testing to their patients. The test takes 10 minutes. I’m happy to meet in person: shreyas@saccade.health

uploaded image

Saccade
Founded:2026
Batch:Fall 2026
Team Size:2
Status:
Active
Location:San Francisco
Primary Partner:Grey Baker